Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01427296 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

A Phase 4 study of Colon Cleansing, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 4
Development phase
2,154
Enrollment target
18
Study locations

NCT01427296 is a Phase 4 study of Colon Cleansing that has completed, run by Bausch Health Americas. The registered enrollment target is 2,154 participants. The trial reports 18 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01427296, a Phase 4 study of Colon Cleansing, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 4
Development phase
2,154 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to compare the safety and efficacy of OsmoPrep tablets versus HalfLytely and Bisacodyl Tablet Bowel Prep Kit in subjects who are undergoing colonoscopy.

Conditions Studied

Interventions

  • DRUG Polyethylene glycol
  • DRUG Oral sodium phosphate solution

Study Locations (18)

North Carolina

  • - Fayetteville
  • - High Point
  • - Raleigh

Georgia

  • - Macon
  • - Suwanee

New York

  • - Great Neck
  • - New York

Ohio

  • - Cincinnati
  • - Mentor

California

  • - San Carlos

Connecticut

  • - Bristol

Maryland

  • - Hagerstown

Michigan

  • - Wyoming

Trial Details

FieldValue
Enrollment Target 2,154 participants
Start Date 2011-09-16
Est. Completion 2014-12-09
Phase Phase 4

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT01427296

The ClinicalTrials.gov registry entry for NCT01427296 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2,154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colon Cleansing appearing as the primary indexed condition, and to 2 interventions - of which Polyethylene glycol is the first listed.

NCT01427296 reports 18 study locations spanning 13 distinct geographic areas - top geographies include North Carolina, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT01427296 about?

NCT01427296 is a clinical study titled "Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing". The purpose of this study is to compare the safety and efficacy of OsmoPrep tablets versus HalfLytely and Bisacodyl Tablet Bowel Prep Kit in subjects who are undergoing colonoscopy.

What is the current status of trial NCT01427296?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,154 participants. The study started on 2011-09-16. Estimated completion is 2014-12-09.

What conditions does trial NCT01427296 study?

This clinical trial studies the following conditions: Colon Cleansing.

What interventions are being tested in trial NCT01427296?

The interventions under investigation include: Polyethylene glycol (DRUG), Oral sodium phosphate solution (DRUG).

Who is sponsoring clinical trial NCT01427296?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01427296 being conducted?

This trial has 18 study locations across California, Connecticut, Georgia, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colon Cleansing

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.